Emergence of SARS-CoV-2 New Variants and Their Clinical Significance

Table 1

The WHO EUL/PQ-approved vaccine for vaccination and its efficacy.

Manufacturer	Name of the vaccine	NRA of record	Platform	Efficacy	Approved schedule for doses	Number of countries approved	Numer of trials/no. of countries
Pfizer	BNT162b2/COMIRNATY Tozinameran (INN)	EMA	Nucleoside-modified mNRA	94%	Two doses, 21–28 days apart	141	70/26
Oxford/AstraZeneca	AZD1222	Core: EMA Non-COVAX	Recombinant ChAdOx1 adenoviral vector encoding the spike protein antigen of SARS-CoV-2	70%	Two doses, 4–12 weeks apart	138	62/30
Bharat Biotech	Covaxin	CTRI	Inactivated, produced in Vero cells	70–90%	Two doses, 28 days apart	14	10/2
Serum Institute of India	Covishield (ChAdOx1_nCoV-19)	DCGI	Recombinant ChAdOx1 adenoviral vector encoding the spike protein antigen of SARS-CoV-2	70%	Two doses, 4–12 weeks apart	47	2/1
Sinopharm/BIBP (Beijing Bio-Institute of Biological Products Co-Ltd)	SARS-CoV-2 Vaccine (Vero Cell), Inactivated (lnCoV)	NMPA	Inactivated, produced in Vero cells	79–86%	Two doses, 21–28 days apart	90	25/12
Sinovac	SARS-CoV-2 Vaccine (Vero Cell), Inactivated	NMPA	Inactivated, produced in Vero cells	50%	Two doses, 14–28 days apart	54	37/9
Moderna	Spikevax	EMA	mNRA-based vaccine encapsulated in lipid nanoparticle (LNP)	95%	Two doses, 28 days apart	83	56/22
Janseen (Johnson & Johnson)	Ad26.COV2.S	EMA	Nonreplicated viral vector recombinant, replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding the (SARS-CoV-2) Spike (S) protein	66%	One dose	108	20/22
Covovax	Serum Institute of India	EMA	Recombinant protein	80–95%	Two doses, 21–28 days apart	3	2/1
Nuvaxovid	(Novavax)	EMA	Recombinant protein	80–95%	Two doses, 21–28 days apart	36	15/12